Multiple Target PFMs
Diseases caused by membrane protein dysfunction (ABC, SLC, GPCR, Ion Channel)
DiscoveryActive
Key Facts
Indication
Diseases caused by membrane protein dysfunction (ABC, SLC, GPCR, Ion Channel)
Phase
Discovery
Status
Active
Company
About Rectify Pharmaceuticals
Rectify Pharmaceuticals is a private, preclinical-stage biotech leveraging its proprietary PFM platform to rectify membrane protein dysfunction, an historically challenging drug target. The company's pipeline is led by a dual-targeted ABCB4/BSEP program for PSC, currently in IND-enabling studies, with parallel programs targeting ABCC6 for vascular calcification and ABCD1/ABCD2 for adrenoleukodystrophy. Backed by venture capital investors like Atlas Venture, Forbion, and Longwood Fund, Rectify aims to deliver first- and best-in-class oral therapies for diseases with high unmet need across hepatobiliary, cardio-renal-metabolic, and neurological therapeutic areas.
View full company profile